Learning Objectives

- Outline the alterations in cytogenetic, molecular abnormalities, NOTCH1, CRLF2 mutations, epigenetic markers in the diagnosis and treatment of patients with acute lymphoblastic leukemia (ALL)

- Select the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with ALL

- Assess the prognostic markers, risk stratification and their impact on clinical practice of patients with chronic lymphocytic lymphoma (CLL)

- Identify and apply individualized treatment strategies based on current and emerging novel therapies for CLL

- Describe the alterations in driver mutations revealing molecular subgroups leading to disease classification and prognostic stratification in acute myeloid leukemia (AML)

- Recognize how compound genotypes are related to clinical outcomes in AML patients treated with novel agents

- Evaluate the first line therapy options for chronic myelogenous leukemia (CML) in chronic phase

- Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of CML

- Cite treatment options for myelodysplastic syndromes